Loading
REM-422 is a small-molecule inhibitor from Remix Therapeutics, in registered phase 2 trials for salivary gland cancers.
REM-422 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Remix Therapeutics, in salivary gland cancers. Described in the registry record as a small molecule mrna inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a small molecule mrna inhibitor; the trial entries below carry the sponsor's wording.
1.REM-422 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"REM-422" OR ABSTRACT:"REM-422") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about REM-422, not a curated reading list.
Shares Adenoid cystic carcinoma, Salivary gland cancers and the tag pipeline.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.